Challenges with Solubility and Bioavailability Video, Part 2
Jun 21, 2013
By Pharmaceutical Technology Editors
Recorded live at the Interphex 2013 trade show, Rita Peters asks Jeffery C. Basham, vice president, business development: From your experience, do you find that the related project work for solubility/bioavailability enhancement is mostly applied for new drug development or do you see it also driving growth in projects for product lifecycle management, for example, to improve dosing schemes/regimes? Can you provide an example of either case?
The past six months has seen some major changes to the sterile manufacturing landscape in Europe. There have been a number of exits and acquisitions that have no doubt grabbed headlines, but has anything really changed?